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Background: Peptidyl-prolyl isomerases (PPIases) are enzymes that assist in the folding of newly-synthesized
proteins and regulate the stability, localization, and activity of mature proteins. They do so by catalyzing revers-
ible (cis-trans) rotation about the peptide bond that precedes proline, inducing conformational changes in target
proteins.
Scope of Review: This review will discuss how PPIases regulate gene transcription by controlling the activity of
(1) DNA-binding transcription regulatory proteins, (2) RNA polymerase II, and (3) chromatin and histone
modifying enzymes.
Major Conclusions:Members of each family of PPIase (cyclophilins, FKBPs, and parvulins) regulate gene transcrip-
tion at multiple levels. In all but a few cases, the exact mechanisms remain elusive. Structure studies, develop-
ment of speciﬁc inhibitors, and new methodologies for studying cis/trans isomerization in vivo represent some
of the challenges in this new frontier that merges two important ﬁelds.
General Signiﬁcance: Prolyl isomerases have been found to play key regulatory roles in all phases of the transcrip-
tion process. Moreover, PPIases control upstream signaling pathways that regulate gene-speciﬁc transcription
during development, hormone response and environmental stress. Although transcription is often rate-
limiting in the production of enzymes and structural proteins, post-transcriptional modiﬁcations are also critical,
and PPIases play key roles here as well (see other reviews in this issue). This article is part of a Special Issue en-
titled Proline-directed Foldases: Cell Signaling Catalysts and Drug Targets.© 2014 The Author. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
PPIases were discovered in 1984 by Gunter Fischer (Editor of this
special issue) and colleagues as enzymes that catalyze the cis/trans
isomerization of peptide bonds that precede the amino acid proline
(X-Pro) [1]. Rotation about these bonds within proteins is normally
restricted due to its partial double-bonded character and steric
hindrance between adjacent α-carbons. (Fig. 1A). The cis-trans inter-
conversion does not require ATP, but instead uses energy derived
from conformational changes in the protein substrates [2,3]. Prolyl
isomerases typically accelerate the cis-trans isomerization of the
peptide bond within peptide substrates by a factor of 103–106 [4–6].
Spontaneous and catalyzed isomerization rates on intact protein sub-
strates are difﬁcult to measure, but are assumed to be much lower
than for peptides due to additional steric considerations. PPIases or
“foldases” as they were originally called, help in the folding of nascent
proteins, but also induce conformational changes in mature proteins,
thereby regulating their activity and/or and interaction with other
proteins [7,8].irected Foldases: Cell Signaling
. This is an open access article underThere are three distinct families of PPIase, the cyclophilins
(CyPs), the FKBPs (FK506 binding proteins), and the parvulins [9–12]
(Fig. 1B). All three are conserved amongst eukaryotes, prokaryotes
and archaea [12–15], with family size increasing with proteome com-
plexity. For example, in the budding yeast, Saccharomyces cerevisiae
there are 8 cyclophilins and 4 FKBPs, while in humans there are 18
cyclophilins and 16 FKBPs [11,16]. In yeast there is one parvulin, Ess1
(essential in yeast), while in humans there are two parvulins, Pin1
(human ortholog of Ess1; protein interacting with NIMA), and Par14/17
which are protein isoforms encoded by the same gene [17–21].
Each family of PPIase has structurally distinct catalytic domains and
they exhibit some differences in substrate speciﬁcity [22–24]. In
eukaryotic cells, PPIases can be found in all cellular compartments
including the cytoplasm, endoplasmic reticulum,mitochondrion, nucle-
us and nucleolus [25].
The cyclophilins and FKBPs can be divided into two broad categories,
the single domain and the multidomain PPIases. The single domain
proteins are abundant and are composed of essentially only the isomer-
ase catalytic domain (Fig. 2) and in the case of cyclophilins and FKBPs,
these are thought to be the major targets of therapeutic drugs
(discussed below). Multidomain cyclophilins and FKBPs contain addi-
tional distinct functional domains that mediate protein-protein or
RNA-binding interactions. Most prominent among these is the TPRthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
CC
C
O
R
C
C
C
C
C
O
R
C
N
C
C
C
isomerase
cistrans
N
A
B
cyclosporin A 
Cyclophilins 
Cpr1-8
FKBPs 
FK506 
rapamycin 
FKBP1-4 
Parvulins 
(juglone) Ess1 
Fig. 1. (A) Depiction of the trans and cis isomeric forms of an X-peptide bond and the in-
terconversion stimulated by prolyl isomerases. (B) Three major families of prolyl isomer-
ase and their respective inhibitors. Juglone is shown in parentheses to indicate it is
relatively non-speciﬁc. Cyclosporin A, FK506 and rapamycin and derivatives thereof are
commonly used as immunosuppressive drugs. Cpr1-8, FKBP1-4 and Ess1 refer to the
yeast proteins.
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tandem [26] (Fig. 2). One important interaction mediated by the TPR
motif is between the immunophilin PPIases and steroid receptor com-
plexes, as will be described below. Parvulins, by contrast, are all small
proteins (parvulus, Latin for very small). In bacteria, parvulins are com-
prised of a PPIase domain [27], while in eukaryotes they can also contain
a N-terminal WW-domain [28] followed by a short linker and a
C-terminal catalytic domain [18,19,29] (Fig. 2). Note that both the
WW-domain and the PPIase domain of Ess1 and its human ortholog
Pin1, bind the same target sequence: phosphorylated Ser/Thr-Pro.
Among the PPIases, only parvulins bind in a phosphorylation-
dependent manner, a feature that is critically important for their func-
tion and has facilitated their study [30,31]. The WW-domain binds
with ~10-fold higher afﬁnity than does the PPIase domain and is
thought to target Ess1/Pin1 to substrates [32].
Members of the cyclophilin and FKBP families are commonly
referred to as immunophilins because theymediate the effects of immu-
nosuppressive drugs cyclosporin A (CsA), FK506 and rapamycin
[33–35]. These drugs bind in the respective active sites of the
immunophilins and block PPIase catalytic activity (Fig. 1B). Oddly
enough, however, their immunosuppressive effects do not result from
inhibition of PPIase activity, but instead from gain-of-function interac-
tions by the immunophilin-drug complexes. Cyclophilin A-CsA and
FKBP12-FK506 complexes inhibit the phosphatase activity of calcine-
urin, which would normally activate the transcription factor NF-AT to
promote T-cell activation [36,37]. The FKBP12-rapamycin complex
inhibits the mTOR (target of rapamycin) kinase blocking signaling in
T-cells in response to cytokine stimulation [38–40]. In addition to their
clinical importance, these immunophilin-drug complexes serve as cau-
tionary examples for why researchers who study PPIases must consider
whether the catalytic activity of the enzyme is, in fact, critical to
the biological process being studied, and what exactly is learned
by using mutational and drug-inhibition studies. This issue was
thoughtfully discussed in a recent review on FKBP25 [41], and will be
noted below.
In contrast to the cyclophilins and FKBPs, the parvulins do not
mediate immunosuppressive effects and do not bind CsA, FK506, or
rapamycin. The relatively non-speciﬁc inhibitor, juglone [42], inhibitsthe activity of parvulins Ess1 and Pin1, and has been used extensively
in mammalian cell culture experiments. However, given its rather
general mechanism of inhibition (covalent modiﬁcation of active-site
cysteines), caution must be used interpreting results of in vivo inhibition
studies, since many different enzymes might also be targeted. [43]. For
example, juglone is a potent inhibitor of RNA polymerase II by blocking
formation of functional pre-initiation complexes [44]. More speciﬁc
inhibitors of parvulins have been isolated and engineered, but are not
widely available. These include peptidomimetics such as D-isomer and
cyclic peptides, and conformationally-locked substrates [43,45–50].
PPIases of all three major families as well as an orphan PPIase, called
Rrd1 in yeast, have all been implicated in regulation of gene transcrip-
tion. Gene transcription is a complex, highly-regulated process that
requires the action of DNA-binding proteins, RNA polymerases, RNA
modifying enzymes, and enzymes that modify DNA and its associated
chromatin. This review is organized into three major sections, how
PPIases control (1) DNA-binding regulatory proteins, (2) RNA polymer-
ase II function, and (3) chromatin structure and histone modiﬁcation.
Related activities in which PPIases have been implicated, such as RNA
splicing and DNA repair, will be mentioned brieﬂy at the end. It should
be noted that a number of excellent reviews covering selected aspects
discussed here have been published elsewhere [11,16,51–58]. Here, I
will emphasize the important concepts, provide speciﬁc examples,
point out future questions, and provide the reader with references for
further inquiry. A synopsis of some of what is covered below is offered
in Table 1.
2. Control of transcription regulatory proteins by PPIases
2.1. Localization of transcription factors
In eukaryotes, transcription of nuclear genes relies on DNA-binding
regulatory proteins (transcription factors) that are synthesized in the
cytoplasm. A key regulatory step is the transport of these proteins into
or out of the nucleus, a process often regulated by signal transduction
pathways in response to extracellular ligands. A number of examples
have emerged that show that PPIases target transcription factors to
regulate nuclear-cytoplasmic shufﬂing. For example, nuclear import
and activation of steroid hormone receptors, which will be considered
separately below, is facilitated by TPR-containing FKBPs and cyclophilin
40 (CyP40). In yeast, cyclophilin A promotes the nuclear export of Zpr1,
a zinc-ﬁnger protein required for growth, although its function as a
transcription factor is not ﬁrmly established [59].
In mammalian cells, the parvulin Pin1 is reported to regulate the
nuclear localization of a number of signaling proteins required for
transcription factor induction as well as the transcription factors
themselves. For example, Pin1 promotes nuclear localization of cyclin
D, [60], β-catenin [61] and NF-κB [62], while it prevents nuclear locali-
zation of NF-AT [63], FOXO4 [64] and CRTC2 [65]. In each case, Pin1
binding to phospho-Ser-Pro motifs [30,32] affects nuclear localization,
however, the underlying mechanisms are different. Pin1 binds to
pSer246-Pro247 in β-catenin reducing its interaction with APC (adeno-
matous polyposis coli protein) [61], which normally shuttles β-catenin
out of the nucleus [66]. Whether Pin1 acts stoichiometrically to physi-
cally block β-catenin interaction with APC, or whether Pin1 catalytic
activity induces conformational changes in β-catenin to block interac-
tion with APC is not known. In the case of NF-AT, Pin1 binds via its
WW domain to a pSer-Pro site normally dephosphorylated by calcine-
urin, thereby trapping NF-AT in the cytoplasm [63]. In the case of the
stress-responsive forkhead transcription factor, FOXO4, Pin1 binding
promotes de-ubiquitylation of FOX04, preventing nuclear entry
(which requires monoubiquitination) [64]. A Pin1 catalytic mutant did
not affect levels of expression of FOXO4 target genes, suggesting that
regulation of FOXO4 by Pin1 requires isomerase activity. Most recently,
Pin1 was shown to bind the nuclear localization sequence (NLS) of
CRTC2 at pSer136-Pro137 [65], although the exact mechanism of action
Fig. 2. Alignment and domain structure of PPIases discussed in this review, divided intomajor families. PPIase, catalytic domain; RRM, RNA-binding domain; TPR, tetratricopeptide repeat;
FK1, active FKBP isomerase domain; FK2, inactive FKBP isomerase domain; CBD, calmodulin binding domain;WW, protein-interaction domain. This is not a complete set and is composed
of PPIases from different organisms. If not indicated, the protein is from yeast or mammals. Sp, S. pombe; At, A. thaliana; Sc, S. cerevisiae; Hs, human; Ec, Escherichia coli.
2019S.D. Hanes / Biochimica et Biophysica Acta 1850 (2015) 2017–2034by Pin1 andwhether its catalytic activity is required is not known. These
studies illustrate that parvulins inﬂuence the localization of proteins by
both catalytic and non-catalytic means. The affects are likely to be
indirect, via changes in substrate availability or conformation that in
turn regulate covalent modiﬁcation by kinases and/or phosphatases.In another mechanism, Pin1 isomerization controls cleavage and
relocation of Notch1 [67]. Initially, Pin1 and p53 were proposed to
prevent processing of Notch from its transmembrane (inactive) form
to its γ-secretase-processed, nuclear localized (activated) form [68]. A
later study shows that Pin1 interacts directly with Notch1 to stimulate
Table 1
Summary of PPIases discussed in this review.
Name
(Family)
Organism(s)1 Associated domain(s)2 Target(s) Function(s) Refs.
Cyclophlins
Cpr1
(CypA)
S. cerevisiae none calcineurin
Rpd3, Set3 (HDACs)
binds cyclosporin A causes cell cycle arrest; decreases silencing at rDNA;
induction of meiosis-speciﬁc genes IME1 IME2; export of Zpr1
[11,36,59,153,212,213]
CypA mammals none calcineurin binds cyclosporin A, mediates immunosuppression by blocking T-cell activation [33,37]
CypB mammals none Prolactin receptor Stimulates DNA binding and activation by Stat5, release of PIAS inhibitor [98]
CsCyP plants none RNA pol II-CTD target of bacterial pathogen PthA2 [152]
Cyp33 mammals RRM RNA, MLL1, H3(?) isomerizes MLL1, converts it to repressor, inhibits H3K4me3 and recruits HDACs;
may isomerize H3 proline(s); may be regulated by RNA
[205–210]
Cyp40 mammals TPR c-Myb; steroid receptors blocks c-Myb DNA binding; localization and activation of steroid receptors [97,137–140]
At Cyp59 Arabidopsis RRM, SR SR-proteins, RNA pol II-CTD; RNA Isomerase activity inhibited by binding speciﬁc 7 nt RNA sequence [149,233]
Rct1 S. pombe RRM, SR SR-proteins, RNA pol II-CTD CTD phosphorylation; RNA pol II elongation (?) [150,151]
At Cyp71 Arabidopsis WD40 LHP1, FAS1, H3 promotes H3K27 methylation, represses HOX genes, histone chaperone activity [215,216]
SR-Cyp
(Matrin)
mammals SR, charged RNA pol II-CTD RNA splicing (?) [146–148]
FKBPs
Fpr1
(FKBP12)
S. cerevisiae none calcineurin,
Tor kinase
binds FK506, rapamycin, drug-complexes cause cell cycle arrest [38]
FKBP12 mammals none calcineurin, mTor, YY1 binds FK506, rapamycin, mediates immunosuppression by blocking
T-cell activation; inhibits mTor signaling, stimulates activation by YY1
[34,35,39,40,99]
Fpr4 S. cerevisiae nucleolin-like histones H3, H4 rDNA silencing (NTS), histone chaperone; isomerizes H3-P16, P30, P38;
keeps Set2-dependent H3K36me3 levels low until gene induction
[218,219,224]
FKBP25
(Fpr4 ortholog)
mammals BTHB YY1, nucleolin, MDM2 stimulates YY1 DNA binding, recruits HDAC1,2; ribosome biogenesis;
degradation of MDM2/protects p53 from destruction
[100,101,229,93]
FKPB51/52 mammals FK2, TPR, CBD steroid receptors - AR, GR, MR, PR, ER; NF-κB; FKBP51 acts negatively, FKBP52 acts positively as co-chaperones for steroid
receptor activation, nuclear localization and transcription activity
[103,120–136]
At FKBP53
(similar to Fpr4)
Arabidopsis acidic, basic H3 histone chaperone activity, rDNA silencing [220]
Parvulins
Parvulin E. coli none membrane proteins protein folding / maturation [27]
Ess1 yeast WW
binds pS/T-P
RNA pol II-CTD, Swi6, Whi5; Rpd3, Spt23 RNA pol II transcription and RNA processing; CTD phosphorylation,
nuclear localization of transcription factors; prevents Spt23 ubiquitylation
[29,53,70,94,95,142,153]
Dodo
(Ess1 ortholog)
Drosophila WW CF2, RNA pol II promotes Ubiq-dependent degradation of CF2; important for pol II function [88,53]
Pin1
(Ess1 ortholog)
mammals,
plants
WW
binds pS/T-P
p53, p73, c-Fos, NF-κB, c-Myc, Oct4, FOXO4; RUNX, SLBP,
etc. RNA pol II-CTD
RNA pol II transcription; signal transduction, transcription factor stability,
nuclear import, activation
[19,45,54,55,60–69,76,77,
85–88,90,91,112–118,234]
Hs Par14 humans basic unknown pre-ribosomal RNA processing [20,53]
Orphan
Rrd1
(Ypa1)
S. cerevisiae hPP2A activator-like RNA pol II-CTD binds rapamycin and effects chromatin association of RNA pol II [154,155]
1Most PPIases listed are also conserved in other organisms; 2Abbreviations are listed in Fig. 2 legend.
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2021S.D. Hanes / Biochimica et Biophysica Acta 1850 (2015) 2017–2034its processing, and thus activate the nuclear, transcriptionally active
form of Notch [69]. Activation required both the catalytic activity of
Pin1 as well as MAPK phosphorylation sites (Ser/Thr-Pro) in the Notch
STR domain known to be important for γ-secretase cleavage. The
disparity with the prior study [68] has been proposed [69] to be due
to increased γ-secretase activity known to occur in p53 knockout mice
used in that study. Thus, Pin1 regulates Notch activity through post-
translational processing.
In yeast, genetic studies linked the Ess1 isomerase to cell cycle
transcription factors Swi6 and Whi5 [70], whose nuclear-cytoplasmic
shuttling is regulated by phosphorylation [71–74]. Ess1 is required for
nuclear localization of Swi6 and Whi5, and Ess1 binds speciﬁcally to
phosphorylated peptides corresponding to the NLS of Swi6, and to the
NLS and nuclear export sequences (NES) of Whi5 [70], which contain
between one and three Ser-Pro binding motifs. As will be described
for RNA polymerase II, cis/trans isomerization of pSer-Pro bonds can
stimulate phosphatase activity and it was suggested that Ess1 regulates
localization of Swi6 and Whi5 by stimulating their dephosphorylation
(a prerequisite for nuclear entry), or by causing conformational changes
that affect interactions with nuclear pore complexes (importins and
exportins) [70].
Higher plants have expanded repertoires of cyclophilins and FKBPs,
many of which are located in the chloroplast, and they contain
parvulin-like PPIases [75,76]. Arabidopsis thaliana contains at least 29
cyclophilins, 23 FKBPs, and three parvulins [77]. PPIases in plants play
a variety of roles in development, ﬂowering, and environmental stress
response [78], which as in mammalian cells are typically mediated via
effects on signal transduction proteins and transcription factors [79].
Examples include Arabidopsis ROF1, an FKBP that activates Hsp90
steroid hormone-receptor complexes as in mammals andmay facilitate
their nuclear import, [80] (discussed below), and PAS1, which interacts
with the transcription repressor FAN in response to auxins and facili-
tates its nuclear localization [81].
2.2. Stability of transcription factors
One common mechanism of regulation of transcription factors by
PPIases is by control of ubiquitin-dependent degradation (reviewed in
[51,54,82]). An example in plants is that of cyclophilin Cyp20-2, which
appears to promote phosphorylation and degradation of the BZR1 tran-
scription factor, a negative regulator of ﬂowering in Arabidopsis [83]. In
mammals, Pin1 can stabilize or promote degradation of target proteins.
An early example is human Pin1 downregulation of c-Myc. Pin1 binds
phosphorylated c-Myc and potentiates its de-phosphorylation by the
PP2A phosphatase, thereby promoting ubiquitin-mediated degradation
[84]. Similarly, Pin1 binds to Smad2/3 proteins in a phosphorylation-
dependent manner and promotes ubiquitin-dependent degradation,
thereby attenuating TGF-β signaling [85]. Smad regulation by Pin1
appears to require PPIase activity, as a Pin1 catalytic site mutant
(C113A) does not degrade Smad2. Pin1 also promotes the degradation
of the normal, but not the disease-associated, epidermal differentiation
factor isoformΔNp63α, a relative of p53 [86], and Pin1 promotes degra-
dation of the mammalian ortholog of the Drosophila Runt transcription
factor, the RUNX3 tumor suppressor [87].
Perhaps themost physiologically compelling example is inDrosophila,
where the Ess1/Pin1 ortholog, called Dodo is important for degradation
of the CF2 transcription factor during oogenesis [88]. CF2 is a down-
stream effector in the EGF-R signaling pathway that is initiated by the
gurken protein, which acts as a region-speciﬁc ligand to specify dorsal
follicle cell fate [89]. Activation of this pathway results in a single phos-
phorylation on CF2 at a MAPK site (Thr40-Pro41). When this site was
mutated (to Ala40-Pro41), in vitro binding by Dodo was reduced, and
in S2 embryonic cells, ubiquitylation decreased and CF2 was stabilized.
In vivo, dodomutants phenocopied both egf-rmutants and CF1 overex-
pression lines, resulting in ventralized embryos, consistent with the
idea that Dodo targets CF2 for degradation in vivo.While the above examples conﬁrm a role for Pin1 in promoting
transcription factor degradation, there are, in fact, more examples of
Pin1 preventing degradation by blocking ubiquitylation. Among the
mammalian transcription factors reportedly stabilized by Pin1 are
NF-κB, p53, c-Jun, c-Fos, Oct4 and Nanog (reviewed by Liou et al., see
references therein) [54], and in plants, AGL24, a MADS-domain protein
[79]. Pin1 was shown to bind to four phospho-Ser/Thr-Pro sites in p53
and stabilize it following DNA damage [90,91]. This likely requires
PPIase activity, as stabilization of p53 in vitro, assayed by protease
sensitivity, required a catalytically active Pin1. In vivo, loss of Pin1
(MEF Pin1 knockout cells) was correlated with increased binding of
Mdm2 to p53. Mdm2 is known to promote ubiquitin-dependent degra-
dation of p53 [92]. Thus, Pin1 stabilizes p53 by preventing its interaction
with Mdm2 [90]. Curiously, a second PPIase, FKBP25, also stabilizes p53
but does so by promoting Mdm2 ubiquitylation and degradation [93].
Thus both Pin1 and FKBP25 keep Mdm2 from p53, the former via
conformational changes in p53, the later via destruction of Mdm2.
In yeast, Ess1 (inappropriately referred to as Pin1 in this study)
stabilizes the transcription factor Spt23 by decreasing its levels of
polyubiquitylation [94]. In an Ess1 catalytic mutant (H164R) [95] or in
“glucose shut-off” strains, reduced Ess1 activity correlated with
increased polyubiquitylation and degradation of Spt23. Finally, Ess1
might promote stability of RNA polymerase II itself, as it was shown
genetically and by 2-hybrid analysis that Ess1 competes with Rsp5, an
E3 ubiquitin ligase, for binding to the large subunit of the polymerase
[96]. Similar to the case for nuclear localization, control of transcription
factor stability by PPIases is likely to be indirect, via inﬂuences on down-
stream covalent modiﬁcation (phosphorylation, ubiquitylation). For a
more comprehensive discussion control of protein stability by Pin1,
see the reviews of Liou et al. and Dilworth et al. [51,54]
2.3. DNA binding and transcriptional activity
While it is often difﬁcult to separate the effects of PPIases on
transcription factor stability and translocation from effects on DNA-
binding and transcriptional activity, there are examples for each family
of PPIase. For the cyclophilins and FKBPs, the most frequently identi-
ﬁed regulatory interactions with transcription factors are with nuclear
steroid-hormone receptors (discussed in 2.4). However, other DNA-
binding proteins are also affected. The earliest example is cyclophilin
40 (Cyp40), which interacts with c-Myb, but not v-Myb, to inhibit its
DNA-binding activity in gel-shift assays [97]. Both the TPR motif and
the PPIase domain of Cyp40 were required for this inhibition, and
cyclosporin A blocked the ability of Cyp40 to inhibit c-Myb DNA-
binding. And in an oft ignored control, the authors showed that inter-
action of Cyp40 with c-Myb is not blocked by the drug interaction.
Together, these data indicate the isomerase activity is required. Using
a different mechanism of regulation, the single domain PPIase,
cyclophilin B (CypB) interacts with the nuclear translocated form of
the prolactin receptor to simulate DNA-binding and transcription acti-
vation by Stat5. It does so by causing the release the Stat inhibitor
PIAS3 [98]. A catalytic mutant of CypB that still interacted with the
prolactin receptor was reduced in its activity, suggesting the isomerase
activity is important for Stat5 activation, although the exact target of
isomerization is not known.
FKBP12 and FKBP25 have been shown to regulate the mammalian
YY1 zinc-ﬁnger transcription repressor [99,100]. FKBP12 (a single
domain PPIase) interacts with YY1 in yeast and mammalian two-
hybrid assays, and in transfected HeLa cells, FKBP12 reduced YY1-
dependent repression, effectively converting YY1 from a repressor into
an activator [99]. The mechanism is not known. FKB25, a multidomain
PPIase also interacts with YY1 but does so via its N-terminal domain,
not its catalytic domain (Fig. 1). The N-terminus of FKBP25 enhances
YY1's DNA-binding activity, and FKBP25 effects on YY1 are not
disrupted by FK506 or rapamycin, indicating that isomerization of YY1
is not a likely mechanism [100]. The N-terminal domain, which forms
2022 S.D. Hanes / Biochimica et Biophysica Acta 1850 (2015) 2017–2034a 5-helix bundle (BTHB) [101], also confers on FKBP25 the ability to
recruit histone deacetylases, HDAC1 and HDAC2, which are important
for repression by YY1.
In lymphocytes, FKBP52, a large multidomain PPIase, regulates the
interferon regulatory factor IRF-4 [102]. FKBP52 uses its TPR motif to
interact with IRF-4 and its prolyl isomerase activity is necessary to
inhibit IRF-4 DNA binding and transactivation of target genes. Changes
in gel migration and protease sensitivity were detected in IRF-4
in vitro upon the addition of FKBP52, consistent with a conformational
change, one that did not occur in the presence of PPIase inhibitor
ascomycin (FK506 analog), suggesting that isomerization of IRF-4 does
occur. Most recently, FKBP51 and FKBP52 have been implicated in
regulation of NF-κB atmultiple levels –nuclear translocation, DNAbind-
ing and transcriptional activity [103]. As in the case of steroid receptors,
FKBP51 was inhibitory, while FKBP52 was stimulatory for gene activa-
tion by NF-κB. Activities of both FKBPs were TPR-dependent, but did
not involve interactions with HSP90. By contrast, PPIase activity was
required for stimulation by FKBP52, but not for inhibition by FKBP51,
as assayed by FK506 sensitivity. This study reveals that the FKBP51/52
duo exerts concerted control over the biological responses mediated
by the NF-κB pathway in a manner analogous to how they control
steroid hormone responses (2.4 below).
The greatest number of interactions between PPIases and transcrip-
tion factors (and signaling proteins) have been reported for the Pin1
isomerase. This is probably because binding sites for Pin1 are easily
identiﬁed (pSer-Pro or pThr-Pro), and Pin1 shows little preference for
ﬂanking residues [23]. In addition, phosphorylation at these sites is
carried out by well-studied cyclin-dependent (CDK) and mitogen-
activated (MAPK) kinases and is ubiquitous in the proteome. These
features prompt many investigators to look a priori for interactions
with Pin1, so it is perhaps not surprising that many, many targets of
Pin1 have been reported [54]. How Pin1 might achieve some degree of
speciﬁcity (if it does) in vivo is still a mystery. Indeed, a recent GST-
Pin1 pulldown/mass spectrometry experiment found over 600 Pin1-
interacting proteins [104]. For more discussion on the “speciﬁcity prob-
lem”, see articles by Hanes [53] and Lippens [105].
An early and intriguing ﬁnding was that Pin1 interacts with the
phosphorylated form of human Spt5, which along with hSpt4 consti-
tutes the DSIF (DRB-sensitive inducing factor) complex [106]. DSIF
together with NELF (negative elongation factor) are responsible for
promoter-proximal pausing of RNA polymerase II in mammalian
cells [107,108]. Upon phosphorylation of DSIF and NELF (and the
C-terminal domain of Rpb1) by P-TEF-b (Cdk9/CyclinT), NELF is released,
and DSIF is “converted” into a positive elongation factor, as in yeast
where Spt4/5 facilitates elongation. The nature of this conversion is not
known, but could potentially involve conformational changes induced by
Pin1-dependent isomerization. In yeast, genetic interactionswere detected
between genes encoding Ess1 and Spt4/5 and Bur1 (yeast Cdk9), suggest-
ing the regulation of Spt4/5 by Pin1/Ess1 may be conserved [109,110].
Pin1 also appears to regulate of p53 family members by a variety of
mechanisms. p53, p63 and p73 and their various isoforms play key roles
in development, cell proliferation, metabolic regulation and tumor
suppression [111]. Each contains a DNA-binding and transcription acti-
vation domain, a proline-rich region and an oligomerization domain.
Ser/Thr-Pro sites within the activation domain, DNA binding domain
and proline-rich domains (PRD) are targets of Pin1 and mediate differ-
ent effects [112]. Apart from regulation of protein stability of p53 and
p63 described above, Pin1 appears to promote p53 DNA binding in
stress-induced cells, as shown by Pin1 RNAi knockdown and p53
chromatin-IP on the p21 promoter [112]. And, as shown for p73, Pin1
promotes the recruitment of the p300 co-activator, which acetylates
p53 (and p73) increasing its ability to activate transcription [113].
Finally, Pin1 helps dissociate the apoptosis inhibitory protein iASPP
from the PRD domain of p53, thus allowing p53 to regulate pro-
apoptotic genes [112]. Thus, Pin1 through a variety of mechanisms,
regulates p53 family functions [114].Similar to its effects on p53 and p73, Pin1 augments DNA binding
activity, p300 interactions, and transcription activation by the
Stat3 transcription factor following growth factor-stimulated phos-
phorylation of Ser/Thr-Pro motifs, and in particular the S727-P728
motif in the Stat3 activation domain [115]. Pin1 also binds the tran-
scription activation domain of c-Fos following mitogen stimulation in
a phosphorylation-dependent manner and increases c-Fos trans-
activation by an unknown mechanism [116]. Pin1 may promote DNA
binding activity of NF-κB in some tissues. Following liver injury, Pin1
promoted transactivation by NF-κB [117], but did not do so by stimulat-
ing nuclear import as reported for other cell types [62]. In fact,
nuclear p65 levels increased in Pin1-/- knockout cells. InsteadPin1 stim-
ulated DNA binding activity in vitro by NF-κB in Pin1+/+ hepatocytes
[117].
Although Pin1 has previously been shown to promote c-Myc degra-
dation in normal cells [84], recent work shows that Pin1 also promotes
c-Myc DNA binding and gene activation, independent of effects on
c-Myc levels [118]. This regulation requires Pin1 PPIase activity and
phosphorylation of c-Myc on S62-P63, and involves Pin1-dependent
recruitment of c-Myc to target gene promoters, along with increased
recruitment of co-activators such as p300 and the GCN5 histone acetyl-
transferase, and the chromatin remodeler SNF5 [118]. Interestingly,
Pin1 seemed to stimulate the dynamics of c-Myc's interaction with
chromatin (both recruitment and eviction), which may be important
for its transactivation function. It was speculated that Pin1-dependent
conformational changes in c–Myc's basic helix-loop-helix leucine zipper
domain (bHLH-LZ) may regulate its DNA binding activity [118]. This
region does have two prolines, but neither is preceded by a Ser or Thr,
so any potential Pin-1 induced conformational changes would occur
elsewhere in the protein.
2.4. Multiple roles for PPIases in nuclear hormone receptor function
Regulation of nuclear (steroid) hormone receptors by PPIases cannot
be neatly broken down into distinct activities. That is because regulation
typically involves multiple interdependent effects on steroid binding,
nuclear translocation, recruitment of receptors to chromatin, and
recruitment of co-activators/co-repressors. And more often than not,
while their PPIase catalytic domains are required for function, their
isomerase activity per se is not. In effect, the large multidomain
TPR-containing immunophilins (FKBPs and cyclophilins) function as
scaffolds and co-chaperones for the assembly and regulation of
Hsp90-receptor complexes. There is an extensive literature on nuclear
receptor regulation by FKBP51, FKBP52 and Cyp40 and I refer the reader
to the following reviews for more discussion and additional citations
[16,52,58,119–122]. Here I will provide a brief overview for how they
regulate steroid-hormone receptor activity, highlighting important
principles and unknowns.
Earlier models for steroid hormone receptor function suggested that
binding of hormone induced a conformational change that released
intracellular receptors fromHsp90 (or other heat shock protein chaper-
ones) allowing them to translocate to the nucleus and regulate
gene transcription [123]. Currently, it is thought that Hsp90 and
immunophilin co-chaperones remain associated with the ligand-
bound receptors and function to escort them into the nucleus,whereup-
on the receptor monomers dimerize, bind DNA, and regulate transcrip-
tion [124] (Fig. 3). Distinct immunophilin-Hsp90-receptor complexes
are formed as a result of competition among different TPR-containing
FKBPs and cyclophilins for binding to Hsp90 [26]. Regulation of speciﬁc
complex formation may underlie developmental and tissue speciﬁcity
of receptor function, but little is known about how this might occur.
FKBP51 and FKBP52were the ﬁrst immunophilins to be identiﬁed as
members of the steroid hormone receptor complexes [125,126]. These
PPIases act, along with Hsp90 and the p23 co-chaperone to control the
activity of all the major “type 1” steroid receptors: androgen receptor
(AR), estrogen receptor (ER), glucocorticoid receptor (GR), progesterone
Fig. 3. Schematic of FKBP co-chaperone activity for nuclear hormone receptor complexes.
FKPB51 is replaced by FKBP52 in activated receptors (HR*, ligand bound), promoting
translocation to the nucleus via interaction with dynein. Once in the nucleus, the complex
dissociates, the hormone receptor dimerizes, binds DNA and regulates transcription. HR,
hormone receptor; Hsp90, heat shock protein chaperone; p23, small co-chaperone pro-
tein. See section 2.4 for details.
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121]). FKBP51 and FKBP52 use their TPRmotifs, and a C-terminal exten-
sion to bind directly to Hsp90 within receptor complexes. Regulation
also requires an intact PPIase domain, but mutational studies clearly
indicate that the isomerase activity is not critical [127]. This serves as
a cautionary tale for other studies that the requirement for a PPIase
domain does not necessarily mean that prolyl isomerization is impor-
tant for the observed effects.
In general, FKBP51 is a negative regulator of nuclear hormone recep-
tor activity, while FKBP52 is a positive regulator. An exception is that
FKBP51 stimulates AR [121]. Both FKBP51 and FKBP52 contain function-
al PPIase catalytic domains (FK1) as well as a second domain (FK2) that
is non-functional (Fig. 2). And, their TPR motifs are interchangeable
[128]. How then does FKBP51 inhibit while FKBP52 activates the same
receptors? An early clue came with ﬁnding that FKBP51 and FKBP52
exchange during GR receptor activation, with unliganded receptor
preferentially associatingwith FKBP51 [129]. Upon hormone activation,
FKBP51 is replaced by FKBP52, which in turn binds the motor protein
dynein [130] to help transport the receptor complex into the nucleus.
Later work also showed that FKBP52 stimulates hormone binding
[131,132], while FKBP51 inhibits hormone binding [129,132,133].
Thus, the currentmodel (Fig. 3) is that the FKBP51-Hsp90 receptor com-
plex is in a repressed state, conﬁned to the cytoplasm. Steroid binding
favors the FKBP52-Hsp90 receptor complex which associates with
dynein-dynactin and is transported along microtubules to the nuclear
pore complex whereupon it is imported into the nucleus. Once in the
nucleus, FKBP52 and Hsp90 dissociate from the receptor, which dimer-
izes, binds DNA and regulates transcription [124,134].
FKBP51 binds poorly with dynein [135], explaining why the
repressed complex stays in the cytoplasm. Functional differences
between FKBP51 and FKBP52 have been mapped to the C-terminal ex-
tension beyond the TPRmotifs and a proline-rich loop on the FK1 PPIase
domain [127,136], but the exactmechanisms of interactionwith dyneinand nuclear import are still not clear, nor is the mechanism of
“uncloaking” once in the nucleus. Curiously, in cells treated with
geldanamycin, which disrupts Hsp90 interactions (and presumably
FKBP interactions), receptor dimers still form in the cytoplasm, with
or without ligand, but these fail to be imported into the nucleus [124].
Cyp40 is the only cyclophilin that carries TPR motifs (Fig. 2), and
perhaps not surprisingly, it binds to Hsp90 and is a member of several
nuclear hormone receptor complexes including AR, ER, PR and GR
complexes [137,138]. Cyp40 regulates Hsp90 ATPase activity, and like
FKBP52, is thought to help increase hormone binding and promote
interaction with dynein to promote nuclear localization [139]. Cyp40
targets the receptor complex via TPR-Hsp90 interactions, while a
surface loop in the Cyp40 PPIase domain is thought to contact the ligand
binding domain of the receptor causing a conformational change that
increases its afﬁnity for hormone [140]. Results of experiments in
yeast using Cpr7 (a Cyp40 ortholog) and mutants thereof, indicate
that the catalytic activity of Cyp40 is not important for receptor activa-
tion. In sum, Cyp40 function closely parallels that of the FKBPs in recep-
tor regulation, and is likely to compete with them for incorporation into
Hsp90-receptor complexes. Given the widespread role of nuclear
hormone receptors in development, physiological responses and
disease, understanding exactly how FKBPs and Cyp40 regulate their
activity remains an important goal.
3. Control of RNA Polymerase II
The most direct way in which prolyl isomerases affect gene
transcription is by targeting the RNA polymerase enzyme itself. In eu-
karyotes, both cyclophilin and parvulin PPIases bind directly to the
carboxy terminal domain (CTD) of Rpb1, the largest subunit of RNA
polymerase II (pol II). And, although PPIases do not seem to have amea-
surable effect on the rate of ribonucleotide addition in vitro [44], they
are nonetheless important for pol II function in vivo [95,141]. Evidence
thus far indicates that PPIases act by controlling the ordered assembly
of RNA pol II subcomplexes that are necessary for efﬁcient elongation,
termination and co-translational RNA processing [95,109,142],
(reviewed in [53]).
3.1. PPIases are linked to RNA polymerase II transcription
The ﬁrst studies linking a PPIase to transcription were those of Hani
et al. [18,141]. They found that temperature-sensitive (ts) mutations in
yeast Ess1 (called PTF1 in their studies) were defective in 3′-end
processing as detected by transcription readthrough of genes with
poly(A)-dependent terminators. At the time, this was a curious result
because many studies were pushing the idea that Pin1, the human
Ess1 ortholog was a “mitotic regulator” whose main targets were cell
cycle proteins [19,143]. [n.b. This view continues today, withmost stud-
ies ignoring potential transcriptional consequences of alterations in
Pin1]. One study, however, found that Pin1 associated with phosphory-
lated pol II in HeLa cell extracts and suggested Pin1 might have a regu-
latory role [144]. Most convincingly, in an unbiased genetic screen, the
author's laboratory discovered that a number of transcription-related
genes, when present at high-copy, rescued the growth defects of
ts-mutations in Ess1 [95]. These included RPB7, and FCP1, which
encodes a CTD phosphatase.Moreover, it was shown that ess1tsmutants
interact genetically with RPB1 reduced-dosage and CTD-truncation
mutants, and with SRB2 mutants (encodes a mediator component),
and that Ess1 binds phosphorylated pol II via its CTD and affected
reporter gene expression [95]. Based on these data, we proposed a
model in which Ess1-dependent isomerization of the CTD controls the
binding and release of proteins required for RNA pol II function [95]
(Fig. 4A). Concurrently, a biochemical fractionation/mass spectrometry
study found Ess1 to be among a number of proteins that bound to a
phospho-CTD column and this was reported in an accelerated publica-
tion [145].
AB
Fig. 4. Role of Ess1 in control of RNA polymerase II and the CTD code. (A) Ess1 binds to the
phosphorylated form of the carboxy-terminal domain (CTD) of the Rpb1 subunit. Ess1 in-
duces conformational changes in the CTD that in turn regulate binding of RNApol II co-fac-
tors (CTD-binding proteins) to the transcription complex. CTD-binding proteins (e.g.
Ssu72, Nrd1, Pcf11, Cgt1) show isomer-speciﬁc (cis vs. trans) recognition. Ess1 also con-
trols phosphorylation of the CTD (not shown). (B) Potential modiﬁcations of the CTD
that collectively constitute the CTD code. Phosphorylation occurs atmultiple different res-
idues and isomerization occurs at the two proline bonds. The CTD in yeast contains 26 re-
peats of this sequence. Not shown are potential glycosylation and othermodiﬁcations that
occur on non-consensus sites in mammals. See sections 3.2–3.4 for details.
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multi-domain cyclophilin bearing serine-arginine rich (SR)-repeats,
typically found in RNA-splicing proteins, was identiﬁed in a two-
hybrid screen using a Gal4-CTD bait [146]. The interaction was mediat-
ed by the SR-domain but no evidence was provided for a role of the
cyclophilin domain. This protein was called SRcyp/CASP10, and local-
ized to the nuclear speckle. It was proposed to target phosphorylated
RNA pol II and induce conformational changes in the CTD to regulate
RNA splicing [146]. This protein was also identiﬁed as human CARS-
CYP [147], and as Matrin-Cyp in rat, which was shown to co-localize
with splicing factors, have PPIase activity comparable to that of tradi-
tional cyclophilins (CypA, CypB), and likely contribute to cyclosporin A
sensitivity of nuclear prolyl isomerase activity [148].
In plants, ArabidopsisAtCyp59, amultidomain cyclophilin containing
an RNA recognition motif (RRM) and an SR-rich region was isolated by
two-hybrid interaction with an SR-protein, but it was also shown to
interact with the CTD of RNA pol II [149]. Although AtCyp59 is not
conserved in S. cerevisiae, an ortholog in Schizosaccharomyces pombe,
Rct1, was shown to be essential for growth and bind to the pol II CTD
and downregulate its phosphorylation levels (on Ser2 and Ser5) [150].
This activity is similar to that of Ess1 (discussed below), and suggests
that in S. pombe, Rct1 may be partially redundant with Ess1 [151].
Rct1 associated with actively transcribed genes (promoter, coding and
3′ regions), and in heterozygous rct1mutants nuclear run-on transcrip-
tion was reduced. This study provides strong evidence that cyclophilins
regulate RNA pol II function [150]. How exactly Rct1 recognizes the CTDandwhether, like Ess1/Pin1, recognition is phosphorylation-dependent,
is not known.
Another plant cyclophilin, CsCyp also interacts with the CTD [152].
CsCyp is a citrus (sweet orange) cyclophilin, related to yeast Cpr1
(CypA), that was shown to mediate the transcriptional response of
bacterial pathogens responsible for citrus canker. Citrus CsCyp possesses
isomerase activity that is cyclosporin A-sensitive, and when over-
expressed, rescues ess1ts mutations in yeast (as does yeast Cpr1) [153].
Interestingly, the bacterial pathogenic protein PthA2 binds the plant
CsCyp and inhibits its isomerase activity, which probably contributes to
the mechanism of transcriptional disregulation and pathogenesis
induced by PthA2 (i.e. via effects on CsCyp regulation of the CTD) [152].
The yeast protein Rrd1 (rapamycin resistant deletion 1), which has
similarity to mammalian phosphotyrosyl phosphatase 2A activator
protein (hPTPA), has been shown to have prolyl isomerase activi-
ty [154]. Rrd1 (also known as Ypa1) interacts with Rpb1 and induces
conformational changes to GST-CTD fusion proteins in vitro in a
rapamycin-dependent manner [155]. ChIP assays indicate that in vivo,
Rrd1 mediates rapamycin effects on the recruitment of RNA pol II to
chromatin, showing differential effects at different loci. In this and a
genome-wide study [156], Rrd1 appears to redistribute RNA pol II
during conditions of stress, such as rapamycin treatment, and likely
does so by changes in phosphorylation of the CTD. In addition, genetic
and ChIP data support the idea that Rrd1 functions in pol II elongation,
although this remains to be demonstrated [156].
3.2. The CTD as a target for covalent and non-covalent modiﬁcation:
The CTD code
The CTD of RNA pol II is a fascinating domain of the Rpb1 subunit
that seems to take on a life of its own. Indeed, it can be transferred
onto other subunits (Rpb4 or Rpb6) where it retains its function
[157]. A casual inspection of the CTD sequence, (Y-S-P-T-S-P-S)n,
immediately reveals why it is of so much interest to prolyl isomerase
researchers, particularly those studying Ess1/Pin1 parvulins, whose
consensus recognition site is pSer-Pro. In yeast, there are 26 almost
identical repeats of this sequence, while in humans there are 52
repeats with additional degeneracy. Prokaryotic and archaeal RNA
polymerases do not contain this motif, nor do eukaryotic RNA poly-
merases I and III. This evolutionary addition to pol II seems to coincide
with the increased complexity of transcription regulation and RNA
processing of eukaryotic mRNA encoding genes. Perhaps the most
interesting structural aspect of the CTD is that, like other low-
complexity and intrinsically-disordered domains, it takes on a deﬁned
structure only when bound to other proteins. In the case of the CTD,
the structures can be very different depending on the binding partner
[158–160]. There is strong evidence that the cis/trans conformations of
the resident prolines are a critical feature of the CTD structures as will
be discussed below (Section 3.4). A number of outstanding reviews
about the evolution, structure and function of the CTD are available
[161–173].
The CTD sequence is likely to have been selected for residues with
maximum versatility. This short motif can be covalently modiﬁed by
phosphorylation, primarily at Ser2, Ser5, and Ser7, but also at Tyr1 and
Thr4 [174]. In mammals, the Ser and Thr residues can also be glycosyl-
ated [175,176], while degenerate Arg7 and Lys7 residues can bemethyl-
ated [177], or potentially acetylated, methylated, sumoylated or
ubiquitylated [166]. Finally, and most importantly for the purposes of
this review, the two Ser-Pro bonds can be non-covalently modiﬁed by
cis/trans isomerization [32,178]. A summary of these modiﬁcations is
shown (Fig. 4B).
Collectively, the different patterns of CTD modiﬁcation are thought
to constitute a “CTD code” for recognition and recruitment of proteins
to the RNA pol II complex [95,179]. Serine phosphorylation, which is
the most easily detected CTD modiﬁcation due to the availability of
phospho-Ser speciﬁc monoclonal antibodies [180], shows characteristic
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ylation are highest at the 5′ ends of genes near the transcription start
site, while Ser2 phosphorylation increases over the body of the gene,
peaking at the 3′ end near the transcription termination site. Phosphor-
ylation of Ser7 remains high while that of Ser5 diminishes sharply
toward the 3′ region. Differential phosphorylation of the CTD is thought
to help the ordered recruitment (and eviction) of RNA pol II co-factors
necessary during the transcription cycle, e.g. for intiation, 5′-capping,
elongation, 3′ cleavage of mRNA, and transcription termination [163,
164,167]. Little is known about the patterns of other covalent and
non-covalent modiﬁcations.
3.3. Ess1 and Pin1 are readers and writers of the CTD code
The Ess1 and Pin1 prolyl isomerases function as both readers and
writers of the CTD code. They are readers because they recognize and
bind only to the phosphorylated forms of the CTD [30–32,178]. They
are writers because once bound they are capable of inducing conforma-
tional changes in the CTD that mediate downstream effects, such as the
binding of CTD-modifying enzymes and co-factors required for RNA pol
II function [142,185–187].
As readers, the binding of Ess1 (and Pin1) to the CTD in vivo depends
on prior action of the CTD kinases [109,187,188] which in yeast include
Kin28 (human Cdk7), which phosphorylates Ser5 (and Ser7), and Ctk1
and Bur1 (human Cdk9 and Cdk12) which phosphorylate Ser2 [162,
189]. Genetic and biochemical evidence shows that Ess1 binds both
pSer5 and pSer2 forms of the CTD, but shows a ~4–5 fold preference
for pSer5-CTD [109,178]. Chromatin IP on individual genes [187]
shows that Ess1 is bound along the entire length of genes including
promoters/5′regions (high pSer5), coding regions (moderate pSer5
and pSer2) and 3′ ends (high pSer2). Genome-wide ChIP studies show
that Ess1 localizes most strongly to the central part of genes where
both Ser2 and Ser5 are phosphorylated (C. Jeronimo, F. Robert pers.
comm.). Pin1 also associates with the phosphorylated form of the RNA
polymerase II, and may do so in a cell-cycle regulated manner [186,
190]. Thus, Ess1 and Pin1 are likely recruited to actively transcribed
genes via phospho-CTD interactions.
As writers of the CTD code, Ess1 and Pin1, once bound, regulate the
interaction of the CTD with other proteins including CTD phosphatases
and kinases [142,187,190]. They do so by increasing the rate of
cis-trans isomerization of the CTD, which in the context of intact
proteins in vivo is probably very low. In vitro, Ess1 stimulates the prolyl
isomerization of phosphorylated-CTD peptides from a spontaneous rate
of less than 1 turnover perminute to N1000/min for a pSer5 peptide and
~200/min for a pSer2 peptide [178]. The key here is that PPIases, which
catalyze the reaction in both directions (cisNtrans and transNcis) and
therefore cannot change the overall equilibrium, still have profound
kinetic consequences on coupled reactions that involve enzymes or
CTD-binding proteins that are speciﬁc for cis or trans substrates.
Themost concrete example of howan isomerase can affect thedirec-
tion of a physiological reaction is that of Werner-Allen et al. [191], who
showed that Ess1 stimulated the CTD phosphatase activity of Ssu72,
which prefers a cis-substrate [191,192]. In solution the low percentage
of cis-isomer available (~12% of total) was rate-limiting for Ssu72 phos-
phatase activity. Addition of Ess1 provided a pronounced kinetic advan-
tage, stimulating the phosphatase activity of Ssu72 on both a small CTD
peptide and on a “full-length”GST-CTD fusion protein (26 repeats). This
stimulationwas saturable as expected and required isomerization, since
catalytic mutants (C120S, S122P, H164R) [178] did not have any ef-
fect [191]. While it is not known what percentage of CTD proline
bonds are in the cis or trans conﬁguration in vivo, these studies illus-
trate how cis-trans interconversion by Ess1 or other PPIases can pro-
vide a kinetic advantage to an isomer-speciﬁc enzyme. Indeed prior
genetic and molecular studies showed that Ess1 controls the phos-
phorylation status of the CTD; Ess1 reduces pSer5 levels by assisting
Ssu72, which is a Ser5-speciﬁc phosphatase [142,184]. Pin1 alsoregulates the phosphorylation status of the CTD and appears to
affect the function of another CTD-phosphatase, Fcp1, as well as
the function of Cdk2 kinase [190].
3.4. Cis/trans speciﬁcity of CTD-binding proteins provides a mechanism for
prolyl isomerase regulation of RNA polymerase II activity
The structures of almost a dozen CTD-binding proteins have been
determined (reviewed in [158–160]). Of these, most, including Cgt1
(capping enzyme) andPcf11 (3′processing factor) bindphosphorylated
CTD-peptides in which the prolines are found in the trans conﬁguration
[193–195]. In contrast, Drosophila and human Ssu72 bind phospho-CTD
peptides in the cis conﬁguration, as does the termination factor Nrd1
[191,192,196]. The high selectivity of these proteins for cis vs. trans
isomers supports the idea that the CTD isomerases, including the
parvulins Ess1 and Pin1, the cyclophilins SR-cyp, AtCyp59/Rct1, and
CsCyp, and the orphan isomerase, hPTPA/Rrd1/Ypa1 play important
roles in RNA pol II regulation. In support of this idea, a number of
transcriptional defects are observed in ess1 mutants and Pin1 knock-
down or knockout cells (reviewed in [53,57]).
The best examples of the effects of PPIases on transcription are found
in yeast. In ess1ts mutant cells, even at permissive temperature, wide-
spread transcription readthrough occurs [95,110,142,185,187]. Speciﬁ-
cally, readthrough is detected on all independently-transcribed (by
pol II) small nucleolar RNA (snoRNA) genes [142]. Importantly, snoRNA
termination is guided by Ssu72, Nrd1 and Pcf11, three of the RNA pol II
co-factors mentioned above, whose CTD-binding structures show cis or
trans speciﬁcity (as well as phospho-Ser preferences). Ssu72 binds and
dephosphorylates the cis-form of pSer5-CTD. Nrd1 binds to the cis
form of phosphorylated Ser5-CTD, while Pcf11 binds the trans
form of Ser2-CTD. Based on genetic, molecular and ChIP data, Ess1
was found to augment Ssu72 function in vivo, and to be required for
Nrd1-dependent termination. Ess1 functions by coordinating the
competition for CTD-binding by Nrd1 and Pcf11 at the 3′ ends of
snoRNA genes [142]. These results provide strongest support to date
for a role of isomerases in implementing (writing) the CTD code to
direct pol II transcription.
It is estimated that asmany ashalf of allmRNAgenes require Ess1 for
efﬁcient poly(A) dependent 3′ processing and/or termination [187]. The
detection of aberrant readthrough and fusion transcripts is facilitated by
the use of RNA decay-deﬁcient backgrounds such as upf1 [187]. The
mechanism of Ess1 in poly(A)-dependent 3′ end formation is unknown
but likely involves Ess1 coordinating the recruitment of 3′-processing
and/or termination factors. Determining their cis/trans speciﬁcity is of
obvious interest. Ess1 is also required to suppress genome-wide expres-
sion of cryptic unstable transcripts (CUTs) [197,198] and stable unanno-
tated transcripts (SUTS) [199] in intergenic regions and within coding
regions in both sense and antisense orientations [142]. In human cells,
Pin1 overexpression in vitro and in vivo was reported to inhibit
transcription and mRNA splicing [186]. The effects on transcription
are not well studied for the other classes of PPIases although there are
clearly transcription-related defects in mutants of Rct1 (cyclophilin)
and Rrd1 (orphan PPIase) [150,156].
3.5. The Trafﬁc Cop model for Ess1 control of RNA polymerase II
Studies on Ess1 and Pin1 lead to a general “Trafﬁc Cop”model of how
isomerases control transcription and co-transcriptional recruitment of
pol II co-factors during the transcription cycle [53]. Ess1 (and other
PPIases that target the CTD) change the conformation of the RNA pol II
CTD by isomerizing prolyl bonds at Ser2-Pro3 and Ser5-Pro6. The
conformational changes induced by Ess1 coordinate the ﬂow of trafﬁc of
CTD binding proteins. There is probably not an absolute requirement
for Ess1 at any given step, as proteinswould eventually bind and release
from the CTD, perhaps in response to spontaneous cis/trans interconver-
sion. However, Ess1 would help make each step more efﬁcient, which
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stress [178]. For example, termination of snoRNAs and mRNAs still oc-
curs correctly ~80% or more of the time, and transcription in vitro
occurs without Ess1/Pin1 [44,110,142,187]. However, without Ess1,
the inefﬁciencies in the transcription cycle, the aberrant RNAs produced,
and cryptic transcription that occurs, probably combine to lead to cell
death, at least in yeast. In organisms where Ess1/Pin1 is not essential,
the defects may be better tolerated or there may exist compensatory
mechanisms such as higher expression of other CTD-binding PPIases
[151,152] However, transcriptional inefﬁciencies could also contribute
to the developmental and disease phenotypes observed in animals
that over- or under- express Pin1 [82,200–202].
4. Control of chromatin structure and histone modiﬁcation
Prolyl isomerases play a number of distinct roles in gene regulation
through alterations in chromatin structure and function [51,203].
These can be categorized as follows (1) controlling the recruitment or
activation of histone modifying enzymes and chromatin remodelers
(2) functioning as histone chaperones, (3) directly isomerizinghistones,
in particular the N-terminal tail of histone H3, and least well character-
ized, (4) a direct or indirect role in higher-order stucture, chromatin
compaction and silencing. Teasing out which nuclear PPIase has which
activity will be a challenge. In addition, some PPIases carry out multiple
distinct functions, such as yeast Fpr4, an ortholog of mammalian FKB25,
which functions as a histone chaperone, a scaffold for assembly of chro-
matin modifying complexes, and a direct histone H3 isomerase, and
Cyp33, which binds RNA, targets a histone modifying enzyme (MLL1)
and isomerizes histone H3 [51]. In this regard, the isolation of allele-
speciﬁc mutations should help in the study of individual functions of a
given PPIase [41].
4.1. PPIases and histone modifying enzymes
PPIases can affect transcription factor activity by regulating
interactions with co-activators and co-repressors, such as histone
acetyltransferases (HATs), histone deacetylases (HDACs), and histone
methyltransferases (HMTs). Examples mentioned above (Section 2.3)
included FKBP25 and its role in recruiting HDACs to the YY1 transcrip-
tion factor, and Pin1, which recruits the p300 (HAT) co-activator.
PPIases can also inﬂuence the assembly and activity of histone
modifying complexes. Perhaps the best understood example is that
of Cyp33 in regulation of the MLL1 (mixed lineage leukemia protein
1) histone H3K4 methyltransferase [204]. Cyp33 limits the activity of
MLL1 complex and effectively converts it from playing an activating
role into a playing repressing role. Cyp33 is a multidomain PPIase con-
taining an N-terminal RRM (RNA binding domain) and a C-terminal
isomerase domain. In Drosophila, Cyp33 interacts with Trithorax, the
MLL1/Set1 ortholog, which trimethylates histone H3 (H3K4me3) and
downregulates the homeotic gene AbdB [205]. Likewise, in mammalian
cells Cyp33 binds MLL1 and downregulates transcription of HOXC8
(ortholog of Drosophila AbdA) and HOXC9 (ortholog of AbdB) [206].
Curiously, Cyp33 upregulates HOXC6 (ortholog of Antp, a more anterior
gene). Cyp33 uses its RRM domain to interact with the third PHD ﬁnger
ofMLL1 [206] and potentiates the recruitment of HDAC1 to the adjacent
repression domain in MLL1 [207]. The effects of Cyp33 on HOX gene
expression require both the RRM and the isomerase domains, and are
sensitive to cyclosporin A, suggesting the catalytic activity is required.
Two outstanding structure-function studies revealed the detailed
mechanisms of action of Cyp33 on MLL1 [208,209] (summarized in
Fig. 5). The structures of both the RRM domain of Cyp33 and the PHD3
of MLL1 were determined, and the surfaces and residues responsible
for their interaction were mapped by NMR and mutagenesis. PHD
domains are known to bind H3K4me3 residues [210]. Both studies
found that H3K4me3 peptides and the RRM of Cyp33 bind to different
surfaces on the PHD3 domain of MLL1. Competition for bindingbetween H3K4me3 peptides and the RRM reduced afﬁnity of the other
by only 2-5 fold. Here the studies differed in interpretation; Park et al.
[208] concluded that binding was mutually exclusive (they observed
5-fold inhibition), while Wang et al. [209] concluded that simultaneous
binding of both the H3 peptide and the RRM of Cyp33 to the MLL PHD
domain was permissible (observed 2-fold inhibition).
A key difference in these studies was that Wang et al. [209] used a
larger fragment of MLL1, which included the PHD3 domain and its
adjacent Bromo domain (which binds acetylated histones). This proved
to be incisive, because at the junction between the domains resides a
conspicuous proline (Pro1629) that is found in the rare cis conforma-
tion. They discovered that in the cis conﬁguration, the Bromo domain
blocks the surface bound by the RRM domain, but does not block the
surface binding the H3K4me3 peptide (Fig. 5). Addition of intact
Cyp33 (catalytically active) allowed RRM binding, but addition of the
RRM alone or a catalytically-deﬁcient Cyp33 did not. Remarkably, a
P1629Amutation,which should generate a trans conformation, allowed
binding of the isolated RRM domain, consistent with the model that
Cyp33 isomerization of the His1628-Pro1629 bond changes the confor-
mation of the MLL1 PHD3 domain to allow simultaneous binding to
methylated histone H3 and the RRM of Cyp33 to form a stable ternary
complex.Wang et al. [209] further postulate that this complex prevents
further “spreading” of the H3K4me3 mark by blocking MLL1 Set-
domain dependent methylation, and helps to recruit HDAC1, together
contributing to transcription repression. Indeed, both groups showed
that Cyp33-dependent repression was accompanied by reductions in
H3K4me3 and H3 acetylation. Park et al. [208] also proposed that
Cyp33 directly isomerizes histone H3. How exactly Cyp33 interaction
with MLL1 at target genes is regulated remains unknown, but it may
involve RNA binding via the RRM domain.
Additional examples of PPIases affecting the activity of histone-
modifying complexes include yeast Ess1 and Cpr1, which interact
genetically and physically with members of the Sin3-Rpd3 HDAC com-
plex [153]. Ess1 appears to inhibit Rpd3 function and increases silencing
at the rDNA locus, while Cpr1 regulates Rpd3 complex assembly, and
decreases silencing at the rDNA locus [153]. Ess1's role in chromatin
modiﬁcation is under study, and initial studies indicate that Ess1 it is
also important for H3K4 trimethylation, as double mutants with Set1
(H3K4 methyltransferase) are synthetic lethal, and H3K4me3 levels
are diminished in ess1ts mutants [187]. For Cpr1, which is best known
as the cytoplasmic target of the cyclosporins, its nuclear function is
intriguing. Cpr1 localizes to the nucleus and is required for induction
of meiosis-speciﬁc genes, IME1 and IME2. Sporulation can be inhibited
by cyclosporin A or by mutations that abolish Cpr1's catalytic activity,
indicating the PPIase activity is necessary for its nuclear function. Cpr1
is also found in complex with the Set3C HDAC complex [211,212].
A proposed model is that Cpr1 induces conformational changes in the
Sin3-Rpd3 complex to relieve repression of IME2 by Ume6 (converting
it from a repressor into an activator), while inhibiting Set3C-
dependent repression of IME1, IME2 and other meiosis-speciﬁc genes
during sporulation [211]. Thus, Cpr1, a single domain PPIase has both
nuclear and cytoplasmic functions and is critical for developmental
gene regulation.
In mammalian cells, Pin1 is reported to promote dephosphorylation
of the linker histone, H1, which would in turn regulate the higher
order structure of chromatin [213]. A number of in vitro and in vivo ex-
periments are suggestive of a model in which Pin1 is recruited to chro-
matin independent of its interactions with the RNA pol II CTD, and by
promoting dephosphorylation of pSer-Pro sites in H1, Pin1 and stabi-
lizes H1's association with chromatin to promote condensation.
In plants, the Arabidopsismultidomain cyclophilin AtCyp71, which
bears four N-terminal WD40 repeats localizes to and represses homeo-
tic genes including KNAT and STM. AtCyp71 binds histone H3 and is
required for placing H3K27me3 repressive marks on target genes
[214]. AtCyp71 likely works by a mechanism that involves recruitment
of LHP1, a HP1-like chromodomain protein that is a subunit of a
Fig. 5. Cyp33 regulation of the mammalian MLL1 histone methyltransferase protein. The MLL1 complex (along with WRAD proteins [234], not shown) trimethylates histone H3 lysine 4
(H3K4). Cyp33 isomerizes Pro1629 inMLL1 causingMLL1 to rearrange to allow binding of the Cyp33 RRMdomain and preventing furthermethylation via the SET domain. This rearrange-
ment may also assist in the recruitment of histone deacetylases (HDAC). Stable binding of Cyp33 via the RRMmay permit further isomerization activity of the PPIase domain, perhaps on
histone H3. Together, these changes convert the MLL1 complex from an activating mode to a repressing mode. See section 4.1 for details.
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ylation marks [215]. How exactly AtCyp71 promotes the deposition of
these marks (placed by a PRC2-like complex) is not yet clear. Interest-
ingly, AtCyp71 also interacts with FAS1 protein, a member of a histone
chaperone complex, suggesting perhaps that AtCyp71 might help
place pre-methylated histones into chromatin [215].4.2. Histone chaperone activity
A number of nuclear-localized PPIases bind directly with histones
and have histone chaperone activity. Histone chaperones facilitate the
exchange of canonical histones (H2A, H2B, H3 and H4), and histone
variants (e.g. H2A.Z) during the assembly and disassembly of nucleo-
somes, for instance during DNA replication or transcription by RNA
polymerases [216]. Two yeast PPIases, S. pombe FKBP39 and its S.
cerevisiae ortholog, Fpr4 were the ﬁrst demonstrated to have histone
chaperone activity in vitro [217]. Both proteins localize to the nucleolus
and Fpr4 was shown to bind to the rDNA locus and be important for
rDNA silencing [217]. Fpr4 histone chaperone activity in vitro activity
is similar to that of acidic nucleosome assembly factor (NAP1), binding
to both H2A-H2B and H3-H4 complexes, with a preference for the latter
[218]. The chaperone activity maps to the N-terminal highly-charged
nucleolin-like domains of FKBP39 and Fpr4 and does not require the
C-terminal isomerase domain [217,218]. In fact, the isomerase domain
inhibits chaperone activity, but not by a mechanism that requires cata-
lytic activity [218]. The isomerase domain is important, however, for
rDNA silencing in vivo [217]. It is likely that Fpr4 contributes to rDNA
silencing by the creation of a repressive nucleosome structure via its
histone chaperone activity, and potentially by direct isomerization of
nucleosomal histones (See section 4.3).
The plant AtFKBP53 is also a histone chaperone and shows structural
and functional similarities with Fpr4. AtFKBP53 facilitates nucleosome
assembly in vitro via an N-terminal acidic domain, interacts preferen-
tially with H3, and localizes to rDNA and promotes silencing [219].
The mammalian FKBP25 protein, lacks the N-terminal acidic domain,
but interacts with nucleolin, which shows similarity to the N-termini
of Fpr4 and AtFKBP53, and may play an analogous role [203]. The
exact mechanism(s) by which PPIases facilitate nucleosome assem-
bly is not known, and is confounded by the fact that, in general, the
isomerase activity, which would provide a logical mechanism for
inﬂuencing histone dimerization or other higher-order assembly, is
not required.4.3. Targeted isomerization of the H3 histone tail
Perhaps in a ﬁtting tribute to the age-old rivalry between Cambridge
and Oxford Universities, groups at these institutions discovered that
prolyl isomerization regulates H3 lysine modiﬁcation [220], and con-
versely that H3 lysine modiﬁcation regulates prolyl isomerization
[221] (summarized in Fig. 6A, and B, respectively). These interesting
studies demonstrate crosstalk between covalent and non-covalent
modiﬁcations of the histoneH3 tail in the regulation of gene expression.
In the Cambridge study, one of the earliest and most inﬂuential papers
in the PPIase-chromatin literature, Nelson et al. [220] showed that
yeast Fpr4 binds directly to histones H3 and H4 and isomerizes
prolines in their amino terminal tails. Isomerization of H3 P38 in turn
regulates lysine methylation at nearby H3K36.
Fpr4 was shown to bind H3 and H4 via its N-terminal nucleolin-like
domain. Fpr4 recognizes a short 8 residue sequence upstream of the 3
prolines in the H3 tail (P16, P30, P38) and one proline in the H4 tail
(P32). Thus, unlike Ess1 and Pin1, recognition is not mediated by the
substrate Pro sites themselves but instead by a nearby sequence.
Using the standard protease-coupled assay [1], Fpr4 was shown to
isomerize the peptide bonds at P30 and P38, but not P16 in H3 and
only marginally at P32 in H4. Later, it was shown that the substrate
design used for the assay, which requires a C-terminal chymotrypsin
site and chromophore (XPF-pNA) [6], inﬂuences the result. Using pep-
tides containing only natural H3 sequences (and an NMR-based
assay), they showed that Fpr4 catalyzes the isomerization of the P16
and P30 bonds at least three-fold better than the P38bond [222]. Impor-
tantly, Nelson et al. [220] showed that addition of Fpr4 to histone H3
peptides or to intact nucleosomes slowed the kinetics of H3K36methyl-
ation by Set2, but did not affect methylation at other sites (e.g. H3K79).
Inhibition of Set2 methylation of H3K36 was dependent upon the
catalytic activity of Fpr4 and the Pro residue at position 38, suggesting
that conformational changes in the H3 tail could regulate this covalent
modiﬁcation.
In vivo, Fpr3 and Fpr4 (which contain nucleolin-like domains) local-
ized to chromatin, but Fpr1 (single domain PPIase) did not. H3K36
trimethylation is typically elevated in the coding region of expressed
genes [223]. Deletion and catalytic-deﬁcient fpr4 mutants did not
show increased levels of H3K36me3 on active genes, but did so on
uninduced genes. The authors found that Fpr4 activity was important
for rapid induction of gene transcription and hypothesized that Fpr4
keeps H3K36 methylation levels low until induction. Isomerization at
H3 P38 could potentially affect recognition and/or catalytic activity of
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nearby K36 residue. Analysis of co-crystals of the human JMJD2A
demethylase with a histone H3 peptide reveal the Lys37-Pro38 bond
to be in the trans conﬁguration, and a P38A mutation does not affect
in JMJD2A's H3K36me3 demethylation activity [224]. Therefore, poten-
tial cis/trans speciﬁcity would likely reside in Set2 binding and/or
methylation activity.
The Oxford group also found isomerization at H3 P16 is important,
but that it is regulated by nearby K14 acetylation [221]. They conducted
a series of clever experiments making use of both point mutations in
histone H3 in yeast, and antisera they developed against cis- and
trans-locked H3 peptides (containing cis- or trans-hydroxylated
prolines). With these in hand, they carried out Western, ChIP, and
genome-wide ChIP-sequencing to examine the detailed relationships
between acetylation at H3K14, isomerization at Ala15-Pro16, and
trimethylation of H3K4. They found that among a set of metabolically
and stress induced genes, acetylation of H3K14 promotes a trans confor-
mation at Ala15-Pro16 that in turn decreases trimethylation at H3K4.
This regulatory crosstalk did not apply to other classes of genes, for
example ribosomal protein genes, or genes highly expressed during
the oxidative phase of the yeast metabolic cycle [225]. They further
show that the decrease in H3K4me3 results from a reduced recruitment
to chromatin of Spp1, a component of the Set1 (H3K4methylase), to the
5′ end of genes, and to an increase in activity of the Jhd2 demethylase
[or potentially its binding; recall that the human JMJD2A structure [224]
mentioned above contains a H3 peptide with a Pro in the trans confor-
mation, consistent with these ﬁndings].A
B
Fig. 6. Prolyl isomerization regulates histone H3 tail modiﬁcation and vice-versa. (A) Fpr4 direct
(and H4, not shown) N-terminal tail and isomerizes P16 and P30 (not shown) and P38. Isome
regulated genes. Thus, PPIase-dependent isomerization, a non-covalent modiﬁcation, regula
Acetylation of histone H3 at K14 causes the bond at Ala15-Pro16 to favor the trans conform
(not shown). The trans form of P16 in turn prevents methylation at H3K4, at least in part by pr
recruitment or activity of the Jhd2 de-methylase (not shown). The cis state of P16 is refractory t
the trans P16 allows binding. See section 4.3 for details.Taking advantage of the trans-speciﬁcity of chymotrypsin cleavage
in a chromogenic assay, they found that acetylation of K14 or mutation
to K14Q (Ac-mimic), but not to K14R (de-Ac mimic) increased the
initial rate of cleavage of a H3 peptide substrate, consistent with these
modiﬁcations promoting a shift toward the trans conformation. K14
modiﬁcations that alter the cis or trans isomerization states at Ala15-
Pro16 also regulate effector protein binding to a downstream acetylated
lysine motif (K18Ac). Speciﬁcally, the Bromo domain of Spt7 binds
K18Ac only when the Ala15-Pro16 is in trans (i.e. when K14 is acetylat-
ed, or if Pro16 is replaced by Val, which favors the trans conformation).
Thus, prolyl isomerization in theH3 tail is regulated in response to cova-
lent modiﬁcation at K14, which in turn has gene-speciﬁc consequences
for additional histone modiﬁcation (H3K4me3) and effector recruit-
ment (to K18Ac). It will be interesting to determine whether the
prolyl-isomerase activity of Fpr4 directed at Ala15-Pro16 reciprocally
affects K14 acetylation, or possibly increases the sensitivity of
the K14Ac - H3K4me3 switch by accelerating the interconversion at
A15-P16.5. Other gene regulatory functions
PPIases have also been implicated in processes that are linked direct-
ly or indirectly to transcription, such as RNA splicing [226], mRNAdecay
[227], DNA repair [104], rDNA silencing and ribosome assembly [228].
Moreover, a number of PPIases contain RNA-binding domains such as
the RRM, that may help localize PPIases or regulate their activity. Aly targets prolines in the histone H3 tail. Fpr4 binds via its nucleolin-like domain to the H3
rization of P38 is necessary for Set2-dependent methylation at H3K36, at least on highly-
tes methylation, a covalent modiﬁcation. (B) Acetylation controls prolyl isomerization.
ation. This seems to occur without the need for an isomerase enzyme, at least in vitro
eventing recruitment of the Set1 complex (via its Spp1 subunit), and possibly by favoring
o binding of Spt7 (a SAGA histone acetyltransferase component) to nearby K18Ac, whereas
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be found in other reviews [226,229–231]5.1. PPIases are regulated by RNA
The Arabidopsis AtCyp59 protein discussed in Section 3.1, which
is highly conserved from S. pombe (Rct1) to humans, contains an
RRM that selectively binds to a seven nucleotide motif in RNA (G
[U/C]N[G/A]CC [A/G] that is found predominantly in exonic sequences
of protein-coding genes [232] and is conserved in S. pombe. In plant
cell cultures, RNAs containing this motif can be co-immunoprecipitated
with AtCyp59, but control RNAs in which this site was mutated cannot.
Most interesting was that the isomerase activity of AtCyp59 is
inhibited by the addition of motif-containing RNA oligonucleotides
(or poly(A) + RNA), but not by control RNA oligonucleotides [232].
Thus, AtCyp59 and its orthologs are RNA-regulated PPIases. Given that
S. pombe Rct1 ortholog targets the RNA pol II CTD, it is possible that
AtCyp59/Rct1 controls the activity of elongating polymerases via its
CTD-interaction, and that binding to the nascent RNA transcript would
reduce its PPIase activity, thus attenuating its effect(s). Regulation by
RNA binding is also likely for Cyp33 in its control of MLL1 [204,205],
as discussed (Section 4.1). How RRM-RNA interactions control the
activity of PPIase domains remains a mystery.5.2. PPIases are linked to ribosome maturation and rDNA silencing
In human cells, FKBP25,which regulates YY1 transcriptional activity,
was also found in the nucleolus and mass spectrometry analysis identi-
ﬁed nucleolin, an RRM-containing protein with a role in ribosomemat-
uration, as a major interacting protein [228]. FKBP25 interactions with
nucleolin are strengthened by rRNA and FKBP25 associates with pre-
60S ribosomal subunits, but not mature ribosomes, suggesting a role
in ribosomebiogenesis, perhaps by regulating ribosomal protein folding
[228]. In yeast, Fpr3 and Fpr4 play a role in suppressing RNA polymerase
II activity in the non-transcribed spacer region (NTS) within the rDNA
locus. Silencing by Fpr3 and Fpr4 seems to occur by a mechanism that
involves compaction of chromatin, and requires PPIase activity and
potentially the isomerization of histone H3 prolines (C. J. Nelson, pers.
comm.).5.3. PPIases control mRNA turnover
In addition to acting on the RNA pol II CTD to inﬂuence mRNA
production, human Pin1 may act later to regulate turnover of speciﬁc
mRNAs. Pin1 was shown to affect the stability of histone mRNAs,
which have short half-lives and are transcribed by RNA pol II but not
polyadenylated [233]. Pin1 targets stem-loop binding protein, SLBP,
which binds a 3′UTR structure in histone mRNAs and is important for
their maturation and function. Pin1 binds the pThr171-Pro172 site
within the RNA-binding domain of SLBP, promoting its dephosphoryla-
tion by PP2A and causing the release of histone mRNAs, which are then
rapidly degraded. In addition, Pin1 targets other sites in SLBP to
promote ubiquitin-mediated degradation. Thus, Pin1 causes decay of
histone mRNAs. Pin1 may also control the stability of poly(A)-
containing mRNAs. A microarray analysis after Pin1 knockdown
identiﬁed sets of genes that seem to be co-regulated and that carry
common 3′ AU-rich regulatory elements [227]. In addition, Pin1
coimmunoprecipitated with two RNA-binding proteins, AU-rich bind-
ing factor 1 (AUF1) and HuR, known to control mRNA turnover [227].
Although additional mechanistic studies are needed, particularly to
rule out effects of Pin1 knockdown on transcription rates of the genes
identiﬁed, it likely that Pin1 controls the stability and RNA-binding
avidity of proteins involved in RNA turnover.6. Summary and future challenges
PPIases control gene transcription in eukaryotes atmultiple levels, as
summarized in Fig. 7. Regulation can begin at the cell periphery with
cleavage of membrane-tethered transcription factors like Notch. In the
cytoplasm, PPIases target a host of transcription regulators, from Swi6
in yeast to NF-κB in humans, to regulate their import into the nucleus.
PPIases control transcription factor fate by stabilization (p53) or degra-
dation (c-Myc), typically via control of ubiquitin-mediated proteolysis.
PPIases work as co-chaperones for steroid hormone receptors to regu-
late their ligand-binding activity and nuclear import, and once in the
nucleus, PPIases control their DNA-binding and transcriptional activity.
PPIases also target RNA polymerase II via interaction with the Rpb1-
CTD. Isomerization of prolines is part of a CTD code for regulating the
activity of RNA pol II via the recruitment of co-factors required for co-
transcriptional RNA processing. PPIases also control mRNA processing
(e.g. 3′-end formation, splicing) and turnover. Finally, PPIases inﬂuence
transcription by altering chromatin structure and function via a variety
of mechanisms that include the recruiting of chromatin and histone
modifying enzymes, acting as histone chaperones, and directly isomer-
izing prolines in the histone H3 tail, which can inﬂuence covalent
modiﬁcation of nearby residues, and vice-versa. Finally, PPIases may
inﬂuence higher-order chromatin structure with effects on gene
silencing.
While it has become clear that prolyl isomerases are involved in
nearly all aspects of gene transcription (and cellmetabolism in general),
in most cases, detailed mechanistic information is lacking. This stems
from a number of current limitations. First, the fact that PPIases carry
out a non-covalent modiﬁcation (in both directions) makes it difﬁcult
if not impossible to track their actions in vivo. Thus, functional studies
are especially challenging. Indirect readouts are useful, such asmonitor-
ing the effects of isomerization on downstream events, such as covalent
modiﬁcation (easier to measure) by enzymes that possess intrinsic
isomer preferences (e.g. Ssu72 CTD phosphatase). Structural and
biochemical studies of additional enzymes – CTD kinases, phosphatases,
histone methylases, demethylases, acetylases, deacetylases etc., to
determine if they have isomer-speciﬁc requirements, will be extremely
useful for understanding coupled reactions and the importance of
PPIase activity in a particular pathway. The use of cis or trans-speciﬁc
antibodies is promising, but this approach needs further development,
such as the generation ofmonoclonal antibodies, and accurate detection
of cis and trans forms in situ as well as in biochemical assays.
A second limitation in determining detailed mechanisms of action
is that the speciﬁcity of PPIases remains poorly understood. For exam-
ple, do the interactions detected by two-hybrid, GST-pull-downs and
immunoprecipitations, the most popular approaches, actually reﬂect
the in vivo situation? If they do, then PPIases would function rather
non-speciﬁcally. If not, how are interactions in vivo restricted?
Here, genetics will help, especially the use of allele-speciﬁc and com-
pensatory mutations. In addition, parallel studies in different
organisms will help identify conserved interactions that are more like-
ly to be important. For FKPBs and cyclophilins, particularly those that
use TPR or other motifs outside the PPIase domain to bind target pro-
teins, deﬁning their actual Pro-containing substrate sites remains an
important goal.
A third limitation is that PPIases can havemultiple functions. Thus, it
is crucial that the nature of the mutant alleles and potential off-target
and pleiotropic effects are considered. For example, interpreting the
effects of knockout alleles for example in MEF cells (-/-), or siRNA
knockdown for a given PPIase (say Pin1) can be tricky due to pleio-
tropic effects on gene expression, including but not limited to de-
fects in transcription factor stability and localization, RNA pol II CTD
regulation, mRNA processing and turnover, and cell cycle effects to
name a few.
Finally, and curiously, the actions of PPIases do not always require
their enzymatic activity. In many cases, PPIases act simply as proline-
Fig. 7. Summary of the roles of prolyl isomerases in control of eukaryotic transcription. Examples of different mechanisms of regulation are shown starting with activation of membrane-
bound transcription regulators by cleavage and release. The mechanisms include regulation of transcription factor stability, nuclear import and retention, ligand binding and activation of
steroid hormone receptors (HR), co-repressor recruitment (HDACs), regulation of histone methyltransferases (HMT), regulation of histone tail modiﬁcation by direct isomerization, and
isomerization of the RNA polymerase CTD. Members of all three families (Fig. 1) participate in these mechanisms of regulation.
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ic from stoichiometric activity is necessary for understanding their
function in a given pathway.
A major future challenge will be to carry out biochemical experi-
ments using puriﬁed components to recapitulate in vivo observations,
and to predict in vivo functional consequences of PPIase activities. For
example, the effect of PPIases on nucleosome assembly, histonemodiﬁ-
cation and in vitro transcription have all been carried out, but further
work is needed in these and other areas. A related challenge will be to
develop speciﬁc inhibitors, for example that can discriminate be-
tween different FKBPs or cyclophlins, or that inhibit parvulins specif-
ically, without targeting unrelated enzymes. Developing FRET-type
assays would also be useful for monitoring PPIase-induced confor-
mation changes in proteins in vivo, and the effects of such changes
on protein-protein interactions and the formation of protein com-
plexes in cells. The ﬁelds of gene transcription and protein modiﬁca-
tion by prolyl isomerization have merged, and there is still much to
learn.
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